The deal will broaden Merck's oncology portfolio as it picks up an antibody-drug conjugate, a class of biological drugs that target tumor cells even as the pharma giant jettisons other parts of its business
Amid the deepest economic crisis since the Great Depression, it has been reported that startups overall face an "existential threat." But while life science startups have slimmer pickings than before, they stand to benefit from the industry's more conservative investment approach.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Philadelphia-based company has an IND open with the FDA and plans to begin its clinical trial in the first half of next year.
The company plans to use the money for a registrational Phase III study of its severe oral mucositis drug, which showed positive results in Phase IIb trial data presented in June.
A previous fund, dating back to 2014, raised $500 million.
A spinoff of Sofinnova Ventures, Healthquest Partners focuses more on diagnostics, medical devices and health IT startups.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Looks like Sofinnova Ventures is bulking up one of its venture funds – up from $50 million a year ago to $110 million today. About $65 million of the Sofinnova HealthQuest Partners fund has been sold, with $45 million still remaining, according to the updated filing. The venture firm is one of the oldest, with roots dating […]